Pdt Partners, LLC Prothena Corp Public LTD CO Transaction History

Pdt Partners, LLC

$1.02 Billion
Q3 2024

A detailed history of Pdt Partners, LLC transactions in Prothena Corp Public LTD CO stock. As of the latest transaction made, Pdt Partners, LLC holds 110,654 shares of PRTA stock, worth $1.55 Million. This represents 0.18% of its overall portfolio holdings.

Number of Shares

110,654

Previous 102,708 7.74%

Holding current value

$1.55 Million

Previous $2.12 Million 12.65%

% of portfolio

0.18%

Previous 0.22%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$16.73 - $24.79 $132,936 - $196,981	7,946 Added 7.74%	110,654 $1.85 Million
Q2 2024 Aug 15, 2024	BUY	$19.54 - $26.15 $2.01 Million - $2.69 Million	102,708 New	102,708 $2.12 Million
Q4 2021 Feb 14, 2022	SELL	$42.11 - $73.26 $186,126 - $323,809	-4,420 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$48.2 - $78.89 $213,044 - $348,693	4,420 New	4,420 $315,000
Q3 2020 Nov 16, 2020	SELL	$9.93 - $13.47 $387,270 - $525,330	-39,000 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$9.56 - $12.51 $167,300 - $218,925	17,500 Added 81.4%	39,000 $408,000
Q4 2019 Feb 14, 2020	SELL	$7.48 - $17.01 $118,842 - $270,254	-15,888 Reduced 42.49%	21,500 $340,000
Q3 2019 Nov 14, 2019	SELL	$6.89 - $10.45 $126,879 - $192,436	-18,415 Reduced 33.0%	37,388 $293,000
Q2 2019 Aug 14, 2019	SELL	$8.85 - $12.49 $27,435 - $38,719	-3,100 Reduced 5.26%	55,803 $590,000
Q1 2019 May 15, 2019	BUY	$10.32 - $14.49 $607,878 - $853,504	58,903 New	58,903 $714,000

Others Institutions Holding PRTA

# of Institutions

184

Shares Held

42.7M

Call Options Held

162K

Put Options Held

102K

View Full List

About PROTHENA CORP PUBLIC LTD CO

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $659M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

More about PRTA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pdt Partners, LLC with notifications on news.

Account